-

Seismic Therapeutic to Participate in Upcoming Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced that company management will participate in the following investor conferences:

Morgan Stanley 22nd Annual Global Healthcare Conference
Date: Thursday, September 5, 2024
Location: New York, NY
Format: Company presentation and 1x1 meetings

Cantor Global Healthcare Conference
Date: Tuesday, September 17, 2024
Location: New York, NY
Format: 1x1 meetings

Stifel 2024 Virtual Immunology and Inflammation Summit
Date: Wednesday, September 18, 2024
Location: Virtual
Format: Company presentation and 1x1 meetings

10th Annual World Medical Innovation Forum
Date: Wednesday, September 25, 2024
Location: Boston, MA
Format: Jo Viney, Ph.D., CEO, will be speaker at the panel presentation titled, “The Disruptors: The Role of Pathway Inhibition in Inflammation and Inflammatory Diseases”

BofA Healthcare Trailblazers Private Company Conference
Date: Wednesday, September 25, 2024
Location: Boston, MA
Format: 1x1 meetings

2024 RBC Capital Markets Biotechnology Private Company Virtual Conference
Date: Tuesday, October 1, 2024
Location: Virtual
Format: Company presentation and 1x1 meetings

Leerink Partners Biopharma Private Company Connect
Date: Wednesday, October 23, 2024
Location: Virtual
Format: 1x1 meetings

About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X @Seismic_Tx.

Contacts

Media
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investors
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com

Industry:

Seismic Therapeutic, Inc.

Release Versions
English

Contacts

Media
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investors
Emiley Demick, Precision AQ
212-362-1200
emiley.demick@precisionaq.com

Social Media Profiles
Seismic/LinkedIn
Seismic/X
More News From Seismic Therapeutic, Inc.

Seismic Therapeutic Appoints Sophie Jones, M.D., as Chief Financial Officer

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the appointment of Sophie Jones, M.D., as the company’s Chief Financial Officer, effective June 18, 2025. In this role, Dr. Jones will lead Seismic’s finance organization and will work closely with the executive team to advance the company’s business operations and strategy across its portfolio of immunology medicines. “We are thrilled to welcome Sophie to the Seismic team as o...

Seismic Therapeutic Doses First Cohort in Phase 1 Clinical Trial of S-4321, a Novel Bifunctional Antibody that Agonizes PD-1 and FcγRIIb Inhibitory Receptors for the Treatment of Autoimmune Disease

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject cohort in a Phase 1 clinical trial of S-4321, a novel bifunctional antibody for the treatment of a range of autoimmune diseases. S-4321 agonizes PD‑1, an inhibitory receptor expressed on effector and regulatory T cells, and Fc-gamma receptor IIb (FcγRIIb), an inhibitory Fc receptor expressed on B cells and antigen presenting cells. The st...

Seismic Therapeutic Forms Translational Medicine Advisory Board with Prominent Experts in Immunology, Rheumatology, Dermatology and Neurology

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the formation of a Translational Medicine Advisory Board to support the company’s focus on accelerating the path to impactful, patient-centric therapies for autoimmune and inflammatory diseases. The charter members of Seismic’s Translational Medicine Advisory Board are J. Michelle Kahlenberg, MD, PhD, Gerald Nepom, MD, PhD, Kevin O’Connor, PhD, and Cornelia Weyand, MD, PhD. The...
Back to Newsroom